The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for blockbuster treatments and substantial returns is clear, the linked risks are also significant. Many of these